Endocrinology
Low Testosterone: The Delivery Experience Is Not Settled.
KEEP heard from 35 people with confirmed low testosterone in June 2026, most currently on prescription TRT. The therapy is familiar, but the delivery experience is not settled. 58% rate their delivery method okay or worse, and 54% report friction in dosing, travel, or discretion. Ease of use leads what patients value, and 89% make evidence-led decisions. The report shows how brands can compete on the experience of taking treatment.
Patient RecruitmentPatient IntelligencePatient Experience
Key Highlights
58% rate their delivery method okay or worse
59% rank ease of use as most important
54% report a treatment-delivery burden
Overview
35 confirmed low testosterone patients show TRT delivery often lands at just okay, leaving room for easier, better-fitting options.
